查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575464

子宮內膜異位症藥物市場：按藥物類型、給藥途徑、患者特徵和最終用戶分類 - 全球預測 2025-2030

Endometriosis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年子宮內膜異位症藥物市值為25.4億美元，預計2024年將達到26.9億美元，複合年成長率為7.11%，2030年將達到41.1億美元，預計將達到1000萬美元。

子宮內膜異位症藥物市場涵蓋一系列用於治療與子宮內膜異位症相關的疼痛和其他症狀的藥物治療，子宮內膜異位症是一種類似於子宮內膜的組織在子宮外生長的疾病。根據衛生組織的數據，子宮內膜異位症影響全球約 10% 的育齡婦女，因此這些藥物至關重要，因為子宮內膜異位症具有慢性且常常使人衰弱的性質。這些藥物主要用於減少發炎、緩解疼痛和緩解荷爾蒙失衡。主要最終用戶包括醫院、診所和家庭護理機構，患者在這些場所尋求醫療干預以管理症狀。市場成長的關鍵因素包括子宮內膜異位症盛行率的增加、認知和診斷率的提高以及口服促性腺激素分泌釋放激素拮抗劑等藥物開發技術的進步。此外，政府對婦女健康措施的支持和投資正在創造新的機會。公司可以透過專注於早期檢測技術和個人化醫療方法來投資資本，從而提供潛在的生產力提升和患者滿意度。然而，藥物成本高、非侵入性治療的可用性有限以及潛在的副作用等限制構成了重大挑戰。此外，新興國家的認知度較低繼續限制市場滲透。創新領域包括開發副作用較少的生物同質激素，以及使用數位健康技術進行早期診斷和治療監測。對免疫調節和血管生成抑制劑等替代療法的研究可能為進一步發展指明道路。這個市場競爭激烈，製藥巨頭投資研發，同時提供利基解決方案的新興企業不斷湧現。為了保持競爭力，公司必須與進行前沿研究的學術機構合作，並維持以患者為中心的研發，以確保治療方法可及且負擔得起。

主要市場統計
基準年[2023] 25.4億美元
預測年份 [2024] 26.9億美元
預測年份 [2030] 41.1億美元
複合年成長率（%） 7.11%

市場動態：揭示快速發展的子宮內膜異位症藥物市場的關鍵市場洞察

子宮內膜異位症藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 政府對婦女健康計畫的承諾和支持，以促進子宮內膜異位症的治療
    • 提高子宮內膜異位症微創治療的可用性和可及性
    • 提高患者對更好的子宮內膜異位症治療方案的認知和宣傳
    • 擴大遠距遠端醫療和數位健康平台以推進子宮內膜異位症管理
  • 市場限制因素
    • 子宮內膜異位症治療方法相關的經濟障礙和高成本
    • 恥辱感和缺乏認知導致子宮內膜異位症患者診斷和治療的延誤
  • 市場機會
    • 奈米技術標靶給藥系統在子宮內膜異位症治療的應用
    • 加大子宮內膜異位症新藥研發投入
    • 擴大醫療保健政策以涵蓋創新的子宮內膜異位症治療和療法
  • 市場挑戰
    • 全球監管合規挑戰影響新子宮內膜異位症藥物的市場准入
    • 供應鏈中斷導致藥物短缺和子宮內膜異位症醫療管理成本增加

波特五力：駕馭子宮內膜異位症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解子宮內膜異位症藥物市場的外部影響

外部宏觀環境因素在塑造子宮內膜異位症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解子宮內膜異位症治療藥物市場的競爭狀況

子宮內膜異位症治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣子宮內膜異位症藥物市場供應商的績效評估

FPNV定位矩陣是評估子宮內膜異位症藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃子宮內膜異位症治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對子宮內膜異位症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 政府對婦女健康計畫的承諾和支持，以增加子宮內膜異位症治療的可近性
      • 提高子宮內膜異位症微創治療的可用性和可及性
      • 提高患者對子宮內膜異位症較好治療方法的認知與支持
      • 擴大遠端醫療和數位健康平台以促進子宮內膜異位症管理
    • 抑制因素
      • 子宮內膜異位症治療方法相關的經濟障礙和高成本
      • 恥辱和缺乏認知導致子宮內膜異位症患者診斷和治療的延誤
    • 機會
      • 奈米技術標靶給藥系統在子宮內膜異位症治療的應用
      • 加大對子宮內膜異位症新治療方法研發的投入
      • 擴大醫療保健政策以涵蓋創新的子宮內膜異位症治療方法和療法
    • 任務
      • 全球監管合規挑戰影響新子宮內膜異位症治療的市場准入
      • 供應鏈中斷導致藥物短缺和子宮內膜異位症醫療管理成本增加
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章：按藥物類型分類的子宮內膜異位症治療市場

  • 促性腺激素分泌釋放激素促效劑
  • 非類固醇消炎劑
  • 口服避孕藥
  • 黃體素治療

第7章子宮內膜異位症藥物市場：依給藥途徑

  • 可注射的
  • 口服藥物

第8章子宮內膜異位症治療藥物市場患者細分

  • 成人用
  • 老年病
  • 小兒科

第9章子宮內膜異位症治療藥物市場：依最終使用者分類

  • 診所
  • 家庭護理設置
  • 醫院

第10章北美和南美子宮內膜異位症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太子宮內膜異位症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲子宮內膜異位症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-2B5802CFEB6F

The Endometriosis Drugs Market was valued at USD 2.54 billion in 2023, expected to reach USD 2.69 billion in 2024, and is projected to grow at a CAGR of 7.11%, to USD 4.11 billion by 2030.

The scope of the endometriosis drugs market encompasses the range of pharmaceutical treatments developed to manage pain and other symptoms associated with endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus. These drugs are essential due to the chronic and often debilitating nature of endometriosis, affecting approximately 10% of women of reproductive age globally, according to figures from health organizations. The application of these drugs primarily focuses on reducing inflammation, alleviating pain, and moderating hormonal imbalances. Key end-users include hospitals, clinics, and homecare settings, where patients seek medical intervention for the condition's management. Crucial market growth influencers include increasing prevalence of endometriosis, heightened awareness and diagnosis rates, and advances in drug development technologies such as oral gonadotropin-releasing hormone antagonists. Additionally, government support and investment in women's health initiatives have opened new opportunities. Companies can capitalize by focusing on early detection technologies and personalized medicine approaches, offering potential productivity gains and patient satisfaction. However, limitations such as high drug costs, limited availability of non-invasive treatments, and potential side effects pose significant challenges. Furthermore, lack of awareness in emerging economies continues to restrict market penetration. Innovation areas ripe for exploration include developing bio-identical hormones with fewer side effects and leveraging digital health technologies for early diagnosis and treatment monitoring. Research into alternative therapies like immunomodulation and angiogenesis inhibitors may present further avenues for development. The nature of this market is competitive, with pharmaceutical giants investing in R&D while startups emerge with niche solutions. To stay competitive, companies should partner with academic institutions for cutting-edge research and maintain a patient-centric approach to drug development, ensuring accessibility and affordability of therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 2.54 billion
Estimated Year [2024] USD 2.69 billion
Forecast Year [2030] USD 4.11 billion
CAGR (%) 7.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endometriosis Drugs Market

The Endometriosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Government initiatives and support for women's health programs boosting endometriosis treatment availability
    • Increasing availability and accessibility of minimally invasive treatments for endometriosis
    • Rising patient awareness and advocacy for better endometriosis treatment options
    • Expansion of telemedicine and digital health platforms facilitating endometriosis management
  • Market Restraints
    • Financial barriers and high costs associated with endometriosis treatment regimens
    • Stigma and lack of awareness leading to delayed diagnosis and treatment in endometriosis patients
  • Market Opportunities
    • The application of nanotechnology for targeted drug delivery systems in endometriosis treatment
    • The increasing investment in research and development for novel endometriosis therapeutics
    • The expansion of healthcare policies to cover innovative endometriosis treatments and therapies
  • Market Challenges
    • Global regulatory compliance challenges affecting the market entry of new endometriosis treatments
    • Supply chain disruptions leading to drug shortages and increased costs in endometriosis healthcare management

Porter's Five Forces: A Strategic Tool for Navigating the Endometriosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endometriosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endometriosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endometriosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endometriosis Drugs Market

A detailed market share analysis in the Endometriosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endometriosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endometriosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endometriosis Drugs Market

A strategic analysis of the Endometriosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endometriosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Allergan Plc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, Ferring Pharmaceuticals, GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Myovant Sciences, Novartis AG, Organon & Co., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Endometriosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Gonadotropins Releasing Hormone Agonists, Nonsteroidal Anti-Inflammatory Drugs, Oral Contraceptive Pills, and Progestin Therapy.
  • Based on Route Of Administration, market is studied across Injectable and Oral Drugs.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Government initiatives and support for women's health programs boosting endometriosis treatment availability
      • 5.1.1.2. Increasing availability and accessibility of minimally invasive treatments for endometriosis
      • 5.1.1.3. Rising patient awareness and advocacy for better endometriosis treatment options
      • 5.1.1.4. Expansion of telemedicine and digital health platforms facilitating endometriosis management
    • 5.1.2. Restraints
      • 5.1.2.1. Financial barriers and high costs associated with endometriosis treatment regimens
      • 5.1.2.2. Stigma and lack of awareness leading to delayed diagnosis and treatment in endometriosis patients
    • 5.1.3. Opportunities
      • 5.1.3.1. The application of nanotechnology for targeted drug delivery systems in endometriosis treatment
      • 5.1.3.2. The increasing investment in research and development for novel endometriosis therapeutics
      • 5.1.3.3. The expansion of healthcare policies to cover innovative endometriosis treatments and therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Global regulatory compliance challenges affecting the market entry of new endometriosis treatments
      • 5.1.4.2. Supply chain disruptions leading to drug shortages and increased costs in endometriosis healthcare management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Endometriosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Gonadotropins Releasing Hormone Agonists
  • 6.3. Nonsteroidal Anti-Inflammatory Drugs
  • 6.4. Oral Contraceptive Pills
  • 6.5. Progestin Therapy

7. Endometriosis Drugs Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral Drugs

8. Endometriosis Drugs Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Endometriosis Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Homecare Settings
  • 9.4. Hospitals

10. Americas Endometriosis Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Endometriosis Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Endometriosis Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Allergan Plc
  • 4. AstraZeneca
  • 5. Bayer AG
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. Endo International Plc
  • 9. Ferring Pharmaceuticals
  • 10. GlaxoSmithKline Plc
  • 11. Janssen Pharmaceuticals, Inc.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Myovant Sciences
  • 15. Novartis AG
  • 16. Organon & Co.
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ENDOMETRIOSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOMETRIOSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENDOMETRIOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOMETRIOSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GONADOTROPINS RELEASING HORMONE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVE PILLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PROGESTIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023